MedTrace Logo

A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent Supra

NCT03255798 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2022-09-09

No results posted yet for this study

Summary

Prospective Evaluation of Open-Angle Glaucoma Subjects treated with two second generation iStents and one iStent Supra

Conditions

  • Glaucoma, Open-Angle

Interventions

DEVICE

G2 and G3

Two iStent inject devices and one iStent supra device

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Principal Investigators

  • Kerry Stephens, OD · Glaukos Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2019-06-06
Completion
2019-06-06
FDA Device
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03255798 on ClinicalTrials.gov